Ouyang P, Brinker J A, Mellits E D, Weisfeldt M L, Gerstenblith G
Circulation. 1984 Sep;70(3):367-76. doi: 10.1161/01.cir.70.3.367.
Although unstable angina can be initially controlled with medical therapy in most patients, there is a high incidence of subsequent death, myocardial infarction, or need for coronary bypass surgery to control symptoms. Identification at the time of presentation of the patient likely to do poorly on continued medical therapy would be useful in advising consideration of surgical therapy. Since coronary arterial spasm may have a significant role in the pathophysiology of unstable angina in some patients, the recently developed calcium channel antagonists may therefore be of particular benefit in the medical therapy of unstable angina. One hundred thirty-eight patients were entered into a randomized double-blind study of the efficacy of adding nifedipine to conventional treatment of unstable angina (nitrates and beta-blockers) and were followed for 18 months. Of these patients, 104 underwent coronary arteriography. A multivariate Cox's hazard function analysis was applied to variables selected from the history, electrocardiographic (ECG) changes during chest pain, and from scintigraphic and coronary arteriographic data to determine those variables most predictive of response to medical therapy. The percentage of the left ventricular myocardium supplied by vessels with 70% or greater luminal stenosis was the most significant variable in influencing failure of medical therapy defined as sudden death, myocardial infarction, or need for bypass surgery. Whether or not the patient received nifedipine was the second most powerful variable, with the use of nifedipine reducing by half the relative risk of failing medical therapy. These were followed by cigarette smoking and presence of global ST segment changes during ischemia. After 18 months the nifedipine group had fewer patients failing medical therapy (p = .02), with fewer patients undergoing coronary bypass surgery (p less than .01). However, nifedipine did not appear to have a preventive effect against myocardial infarction or death. Kaplan-Meier actuarial curves confirmed that medical therapy was significantly less successful in the presence of increasing numbers of significantly stenotic vessels (p = .03). However, nifedipine provided a significant beneficial effect in patients with two or more stenotic vessels (p less than .01) and in whom 50% or more of the myocardium was supplied by vessels with 70% or greater stenosis (p = .01). Thus, although patients with advanced obstructive coronary disease have the greatest likelihood of unfavorable outcomes, the addition of nifedipine is of significant benefit.(ABSTRACT TRUNCATED AT 400 WORDS)
虽然大多数不稳定型心绞痛患者最初可通过药物治疗得到控制,但随后发生死亡、心肌梗死或需要进行冠状动脉搭桥手术以控制症状的发生率很高。在患者就诊时识别出继续药物治疗可能效果不佳的患者,对于建议考虑手术治疗会很有帮助。由于冠状动脉痉挛在某些不稳定型心绞痛患者的病理生理学中可能起重要作用,因此最近开发的钙通道拮抗剂可能对不稳定型心绞痛的药物治疗特别有益。138例患者进入一项关于在不稳定型心绞痛的常规治疗(硝酸盐和β受体阻滞剂)中加用硝苯地平疗效的随机双盲研究,并随访18个月。这些患者中,104例接受了冠状动脉造影。对从病史、胸痛时的心电图(ECG)变化以及闪烁扫描和冠状动脉造影数据中选取的变量应用多变量Cox风险函数分析,以确定那些最能预测药物治疗反应的变量。管腔狭窄70%或以上的血管所供应的左心室心肌百分比是影响定义为猝死、心肌梗死或需要搭桥手术的药物治疗失败的最显著变量。患者是否接受硝苯地平是第二有力的变量,使用硝苯地平可使药物治疗失败的相对风险降低一半。其次是吸烟和缺血时整体ST段改变的存在。18个月后,硝苯地平组药物治疗失败的患者较少(p = 0.02),接受冠状动脉搭桥手术的患者较少(p < 0.01)。然而,硝苯地平似乎对心肌梗死或死亡没有预防作用。Kaplan-Meier精算曲线证实,在存在越来越多严重狭窄血管的情况下,药物治疗的成功率显著降低(p = 0.03)。然而,硝苯地平在有两条或更多狭窄血管且50%或更多心肌由狭窄70%或以上的血管供应的患者中提供了显著的有益效果(p < 0.01)。因此,虽然患有晚期阻塞性冠状动脉疾病的患者出现不良结局的可能性最大,但加用硝苯地平有显著益处。(摘要截短至400字)